But combining the two [Lambda and Baraclude] might help reduce resistance.
Resistance is essentially a non-issue for Baraclude, so adding Lambda for this purpose alone is a non-starter.
Also, wasn't there a study showing that IFN are more effective than direct antivirals in certain population and vice versa?
I’m not sure what you’re referring to. Notwithstanding VRUS’ outsized claims about Clevudine (which are now moot), ifn is clearly more efficacious than direct antivirals in achieving HBsAg seroconversion, but ifn is rarely used in HBV due to its tolerability profile.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”